In summary, our results indicated that the miR-3656/ACAP2 axis promotes cell migration and invasion through the AKT and β-catenin signaling pathways and might represent a novel target in ESCC therapy. The gene discussed is ACAP2; the disease is esophageal squamous cell carcinoma.